Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

被引：5
|
作者：
Minchom, Anna Rachel
Girard, Nicolas
Bazhenova, Lyudmila
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Trigo, Jose
Viteri, Santiago
Backenroth, Daniel
Bhattacharya, Archan
Li, Tracy
Mahadevia, Parthiv
Bauml, Joshua
机构：
[1] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[2] Inst Curie, Paris, France
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Calif Irvine, Orange, CA 92668 USA
[5] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI USA
[6] IBIMA, Hosp Univ Virgen Victoria & Reg, Malaga, Spain
[7] Grp QuironSalud, Ctr Med Teknon, Inst Oncol Dr Rosell, Barcelona, Spain
[8] Janssen R&D, Raritan, NJ USA
[9] Janssen R&D, High Wycombe, PA, England
[10] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9052
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
    Zhang, Mai
    Huang, Qian
    Yu, Min
    Xue, Jianxin
    Huang, Meijuan
    Lu, You
    Zhang, Yan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (04) : 797 - 807
  • [42] Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
    Liu, Geoffrey
    Nyaw, Shi Feng
    Mok, Tony S. K.
    Curcio, Hubert
    Cortot, Alexis B.
    Kam, Tsz Yeung
    Descourt, Renaud
    Chik, Yin Kwan
    Cheema, Parneet
    Gwinnutt, James M.
    Churchill, Eric N.
    Nyborn, Justin
    Curran, Eileen
    Savell, Alexandra
    Yin, Yu
    Chong, Katie
    Tanaka-Chambers, Yuka
    Kretz, Julian
    Cadranel, Jacques
    CANCER MEDICINE, 2025, 14 (03):
  • [43] Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
    Tian, P.
    Wu, L.
    Zhou, C.
    Tan, J.
    Wang, K.
    Luo, F.
    Liu, Y.
    Guo, Y.
    Li, Y.
    Liu, Z.
    Gong, Y.
    Wang, Y.
    Li, W.
    ANNALS OF ONCOLOGY, 2023, 34
  • [44] Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)
    Lee, V. H. F.
    Lin, M.
    Curran, E.
    Yin, Y.
    Churchill, E.
    Allen, S.
    Abovich, J.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1059 - S1059
  • [45] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hidetoshi Hayashi
    Makoto Nishio
    Michiko Takahashi
    Hiroaki Tsuchiya
    Mami Kasahara-Kiritani
    Advances in Therapy, 2023, 40 : 4545 - 4560
  • [46] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hayashi, Hidetoshi
    Nishio, Makoto
    Takahashi, Michiko
    Tsuchiya, Hiroaki
    Kasahara-Kiritani, Mami
    ADVANCES IN THERAPY, 2023, 40 (10) : 4545 - 4560
  • [47] AMIVANTAMAB VERSUS REAL-WORLD CLINICAL PRACTICE IN EUROPE AND THE US FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS
    Chouaid, C.
    Girard, N.
    Kron, A.
    Scheffler, M.
    Knott, C.
    Bosquet, L.
    Trigo, J.
    Viteri, S.
    Sebastian, M.
    Popat, S.
    Rahhali, N.
    Toueg, R.
    Rodrigues, B.
    Diels, J.
    Schioppa, C. A.
    Cabrieto, J.
    Sermon, J.
    Perualila, N. J.
    Erdmann, N.
    Mielke, J.
    Nematian-Samani, M.
    Pfaira, I
    Martin-Fernandez, C.
    Mahadevia, P.
    Li, T.
    Pick-Lauer, C.
    Adamczyk, A.
    Penton, J.
    Wolf, J.
    VALUE IN HEALTH, 2022, 25 (12) : S32 - S32
  • [48] Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
    Christopoulos, P.
    Prawitz, T.
    Hong, J-L.
    Lin, H. M.
    Hernandez, L.
    Jin, S.
    Tan, M.
    Proskorovsky, I.
    Lin, J.
    Zhang, P.
    Patel, J.
    Ou, S-H. I.
    Thomas, M.
    Stenzinger, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S49
  • [49] Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)
    Ji, Wonjun
    Oh, In-Jae
    Park, Cheol-Kyu
    Lee, Sung Yong
    Choi, Juwhan
    Lee, Jae Cheol
    Kim, Jiwon
    Lee, Seung Hyeun
    CANCERS, 2023, 15 (23)
  • [50] Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies
    Prelaj, A.
    Le, X.
    Proto, C.
    Baik, C. S.
    Tchekmedyian, N.
    Heymach, J.
    Bhat, G.
    Cornelissen, R.
    ANNALS OF ONCOLOGY, 2023, 34
12345